Bellicum Pharmaceuticals Inc (BLCM) Expected to Announce Quarterly Sales of $80,000.00

Wall Street analysts expect Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to announce $80,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The lowest sales estimate is $30,000.00 and the highest is $100,000.00. Bellicum Pharmaceuticals reported sales of $130,000.00 in the same quarter last year, which would suggest a negative year over year growth rate of 38.5%. The business is scheduled to issue its next earnings results on Monday, May 14th.

According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full year sales of $80,000.00 for the current financial year, with estimates ranging from $120,000.00 to $400,000.00. For the next year, analysts expect that the company will post sales of $570,000.00 per share, with estimates ranging from $300,000.00 to $1.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Bellicum Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.08. The business had revenue of ($0.07) million for the quarter, compared to the consensus estimate of $0.08 million.

Several equities analysts recently issued reports on BLCM shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Citigroup lifted their price target on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, February 16th. Wells Fargo lowered shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price target on the stock. in a research report on Wednesday, January 31st. ValuEngine lowered shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $16.88.

Shares of NASDAQ BLCM traded down $0.16 during trading hours on Thursday, reaching $6.56. The stock had a trading volume of 596,847 shares, compared to its average volume of 609,700. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37. The firm has a market capitalization of $220.23, a price-to-earnings ratio of -2.31 and a beta of 0.44. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $14.49.

In related news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the business’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $8.20, for a total transaction of $7,222,027.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 1,141,822 shares of company stock worth $9,475,583 in the last ninety days. 18.77% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. boosted its holdings in shares of Bellicum Pharmaceuticals by 47.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock worth $1,516,000 after purchasing an additional 41,995 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Bellicum Pharmaceuticals in the fourth quarter valued at $343,000. X Square Capital LLC purchased a new position in shares of Bellicum Pharmaceuticals in the fourth quarter valued at $544,000. Dimensional Fund Advisors LP purchased a new position in shares of Bellicum Pharmaceuticals in the second quarter valued at $474,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Bellicum Pharmaceuticals in the third quarter valued at $4,723,000. 54.57% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.wkrb13.com/2018/04/01/bellicum-pharmaceuticals-inc-blcm-expected-to-announce-quarterly-sales-of-80000-00.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply